Press "esc" to clear
Go to Advanced Search

Showing results

110 of 463

No Images
or Multimedia

  • Embargo expired:
    11-Jan-2018 1:00 PM EST

Article ID: 687762

Discovery Suggests New Strategy for Attacking High- Profile but Elusive Target in Cancer

Dana-Farber Cancer Institute

A discovery by scientists at Dana-Farber Cancer Institute and University of Texas Southwestern Medical Center presents drug developers with an entirely new tack in targeting one of the most-wanted molecular culprits in cancer.

Released:
11-Jan-2018 1:00 PM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Cancer, Cell Biology, Local - Massachusetts, Local - Boston Metro, Grant Funded News

No Images
or Multimedia

  • Embargo expired:
    4-Jan-2018 2:00 PM EST

Article ID: 687429

Mechanism for Resistance to Immunotherapy Treatment Discovered

Dana-Farber Cancer Institute

Two research groups from Dana-Farber Cancer Institute have independently discovered a genetic mechanism in cancer cells that influences whether they resist or respond to immunotherapy drugs known as checkpoint inhibitors. The scientists say the findings reveal potential new drug targets and might aid efforts to extend the benefits of immunotherapy treatment to more patients and additional types of cancer.

Released:
3-Jan-2018 2:50 PM EST
EXPERT AVAILABLE
Comment

Channels:

Cancer, Cell Biology, Genetics, Immunology, Local - Massachusetts, Local - Boston Metro, All Journal News

No Images
or Multimedia

  • Embargo expired:
    12-Dec-2017 9:30 AM EST

Article ID: 686447

Dana-Farber/Brigham and Women’s physician wins prestigious 2017 William Dameshek Prize from the American Society of Hematology

Dana-Farber Cancer Institute

• Benjamin Ebert, MD, PhD, current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting • Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS)

Released:
7-Dec-2017 2:30 PM EST
EXPERT AVAILABLE
Comment

Channels:

Blood Disorders, Cancer, Cell Biology, Children's Health, Local - Massachusetts, Local - Boston Metro, Medical Meetings

No Images
or Multimedia

  • Embargo expired:
    11-Dec-2017 5:30 PM EST

Article ID: 686443

Study Identifies Agent That Can Reverse Resistance to Targeted Drug in Some Leukemia Cell Types

Dana-Farber Cancer Institute

• Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find • Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients

Released:
7-Dec-2017 2:30 PM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Blood Disorders, Cancer, Cell Biology, Local - Massachusetts, Local - Boston Metro, Medical Meetings

No Images
or Multimedia

  • Embargo expired:
    10-Dec-2017 5:15 PM EST

Article ID: 686442

Study Shows Combining Chemotherapy with Targeted Drug Boosts Response in Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

Released:
7-Dec-2017 2:25 PM EST
EXPERT AVAILABLE
Comment

Channels:

Blood Disorders, Cancer, Cell Biology, Local - Massachusetts, Local - Boston Metro, Medical Meetings

No Images
or Multimedia

  • Embargo expired:
    10-Dec-2017 9:45 AM EST

Article ID: 686439

Sequencing Offers Clues to Progression Toward Multiple Myeloma

Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn’t show outward symptoms.

Released:
7-Dec-2017 2:30 PM EST
EXPERT AVAILABLE
Comment

Channels:

Blood Disorders, Cancer, Cell Biology, Genetics, Local - Massachusetts, Local - Boston Metro, Medical Meetings

No Images
or Multimedia

  • Embargo expired:
    10-Dec-2017 8:30 AM EST

Article ID: 686440

Tracking How Multiple Myeloma Evolves by Sequencing DNA in the Blood

Dana-Farber Cancer Institute

Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments.

Released:
7-Dec-2017 2:20 PM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Blood Disorders, Cancer, Cell Biology, Local - Massachusetts, Local - Boston Metro, Medical Meetings

No Images
or Multimedia

  • Embargo expired:
    10-Dec-2017 8:00 AM EST

Article ID: 686441

Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

Dana-Farber Cancer Institute

• Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis • Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

Released:
7-Dec-2017 2:00 PM EST
EXPERT AVAILABLE
Comment

Channels:

Blood Disorders, Cancer, Cell Biology, Children's Health, Pharmaceuticals, Local - Massachusetts, Local - Boston Metro, Medical Meetings

No Images
or Multimedia

  • Embargo expired:
    10-Dec-2017 6:00 AM EST

Article ID: 686444

Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

Dana-Farber Cancer Institute

Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

Released:
7-Dec-2017 2:15 PM EST
EXPERT AVAILABLE
Comment

Channels:

Blood Disorders, Cancer, Medical Meetings, Local - Massachusetts, Local - Boston Metro

No Images
or Multimedia

  • Embargo expired:
    9-Dec-2017 5:00 PM EST

Article ID: 686438

Study Explores Use of Checkpoint Inhibitors After Relapse From Donor Stem Cell Transplant for Hematologic Cancers

Dana-Farber Cancer Institute

Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent – nivolumab – indicate that along with signs of effectiveness, it also produced significant side effects at the dose initially studied. The findings indicate a need for further clinical trials in this group before being considered for off-label use with these patients, Dana-Farber Cancer Institute investigators report.

Released:
7-Dec-2017 2:15 PM EST
EXPERT AVAILABLE
Comment

Channels:

All Journal News, Blood Disorders, Cancer, Cell Biology, Children's Health, Stem Cells, Transplantation, Local - Massachusetts, Local - Boston Metro, Scientific Meetings


Showing results

110 of 463





Chat now!